J. Carmichael

756 total citations
23 papers, 475 citations indexed

About

J. Carmichael is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Carmichael has authored 23 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Carmichael's work include PARP inhibition in cancer therapy (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). J. Carmichael is often cited by papers focused on PARP inhibition in cancer therapy (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). J. Carmichael collaborates with scholars based in United Kingdom, United States and Canada. J. Carmichael's co-authors include Adrian L. Harris, Daniel Rea, Helaine Rockett, Dennis Talbot, Trivadi S. Ganesan, P. A. Philip, N Stuart, Frances R. Balkwill, George R. Pettit and P. Thavasu and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

J. Carmichael

21 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Carmichael United Kingdom 10 243 204 84 58 51 23 475
Chris Benz United States 12 255 1.0× 231 1.1× 86 1.0× 83 1.4× 76 1.5× 27 539
K Csóka Sweden 12 207 0.9× 246 1.2× 47 0.6× 44 0.8× 19 0.4× 19 503
Ronald Drengler United States 13 487 2.0× 296 1.5× 104 1.2× 70 1.2× 24 0.5× 27 701
Sheeba Irshad United Kingdom 15 353 1.5× 254 1.2× 70 0.8× 134 2.3× 68 1.3× 47 654
Lidija Beketić-Orešković Croatia 13 276 1.1× 288 1.4× 36 0.4× 102 1.8× 53 1.0× 37 591
Ornella Sanfilippo Italy 12 290 1.2× 241 1.2× 59 0.7× 172 3.0× 66 1.3× 28 550
G. R. Boniface Australia 10 239 1.0× 182 0.9× 60 0.7× 41 0.7× 9 0.2× 23 476
Kristin Padavic United States 9 205 0.8× 394 1.9× 68 0.8× 111 1.9× 48 0.9× 10 612
Grażyna Pasz‐Walczak Poland 11 241 1.0× 190 0.9× 37 0.4× 99 1.7× 51 1.0× 36 431
Hiroko Taga Japan 11 78 0.3× 341 1.7× 41 0.5× 58 1.0× 23 0.5× 33 644

Countries citing papers authored by J. Carmichael

Since Specialization
Citations

This map shows the geographic impact of J. Carmichael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Carmichael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Carmichael more than expected).

Fields of papers citing papers by J. Carmichael

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Carmichael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Carmichael. The network helps show where J. Carmichael may publish in the future.

Co-authorship network of co-authors of J. Carmichael

This figure shows the co-authorship network connecting the top 25 collaborators of J. Carmichael. A scholar is included among the top collaborators of J. Carmichael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Carmichael. J. Carmichael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davidson, Joseph, Alena Uus, Jacqueline Matthew, et al.. (2021). Fetal body MRI and its application to fetal and neonatal treatment: an illustrative review. The Lancet Child & Adolescent Health. 5(6). 447–458. 30 indexed citations
2.
Story, Lisa, Caroline L. Knight, Alison Ho, et al.. (2021). Maternal and fetal incidental findings on antenatal magnetic resonance imaging. Pediatric Radiology. 51(10). 1839–1847. 3 indexed citations
3.
Carmichael, J., et al.. (2010). Imaging chronic renal disease and renal transplant in children. Pediatric Radiology. 40(6). 963–974. 2 indexed citations
4.
Ang, Joo Ern, Helen Swaisland, André T. Brunetto, et al.. (2010). 405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. European Journal of Cancer Supplements. 8(7). 128–129. 12 indexed citations
5.
Knights, Charlotte, Christine M. Chresta, Lucy C. Riches, et al.. (2009). Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer. Molecular Cancer Therapeutics. 8(12_Supplement). A114–A114. 5 indexed citations
6.
Finn, RS, Alexander Yuk Lun Lau, Ondrej Kalous, et al.. (2009). Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents.. Cancer Research. 69(2_Supplement). 1038–1038. 5 indexed citations
7.
8.
Anderson, Heather, J. Carmichael, M. Nicolson, P. Hopwood, & Nick Thatcher. (2001). Chemotherapy and quality of life in advanced NSCLC – reply. British Journal of Cancer. 85(1). 137–138. 1 indexed citations
9.
10.
Pawel, Joachim von, K. Hans, D Moro, et al.. (1997). Topotecan (Hycamtin™) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study. European Journal of Cancer. 33. S229–S229. 15 indexed citations
11.
Carmichael, J., et al.. (1997). A phase I study to investigate alternate sequencing of the combination gemcitabine followed by carboplatin in NSCLC. European Journal of Cancer. 33. S230–S230. 6 indexed citations
12.
Łacko, Aleksandra, et al.. (1997). CEF chemotherapy for advanced gastro-oesophageal cancer. European Journal of Cancer. 33. S281–S281. 2 indexed citations
13.
Anderson, Helén, B. Cottier, M. Nicolson, et al.. (1997). 24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 18. 9–9. 21 indexed citations
14.
Philip, P. A., C. Thompson, J. Carmichael, et al.. (1993). A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy.. PubMed. 53(23). 5649–53. 6 indexed citations
15.
Philip, P. A., Daniel Rea, P. Thavasu, et al.. (1993). Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor   Induction In Vivo. JNCI Journal of the National Cancer Institute. 85(22). 1812–1818. 151 indexed citations
16.
Rusthoven, James J., Leslie Levin, J. Mazurka, et al.. (1991). Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor. JNCI Journal of the National Cancer Institute. 83(23). 1748–1753. 23 indexed citations
17.
Rusthoven, James J., L Levin, E. Eisenhauer, et al.. (1991). A phase I study of GM-CSF, cyclophosphamide (CP), and escalating doses of carboplatin (CBDCA) in chemotherapy-Naïve patients with ovarian cancer. Gynecologic Oncology. 40(2). 169–170. 2 indexed citations
18.
Gamson, Janet, Andrea Russo, Norman R. Friedman, et al.. (1988). Chinese hamster pleiotropic multidrug-resistant cells are not radioresistant.. PubMed. 187–91. 33 indexed citations
19.
Harris, Adrian L., B.M.J. Cantwell, J. Carmichael, et al.. (1987). Use of LH-RH agonist zoladex in postmenopausal breast cancer. Journal of Steroid Biochemistry. 28. 110–110. 2 indexed citations
20.
Lewis, Alexander D., et al.. (1987). The role of glutathione in determining the response of normal and tumour cells to anticancer drugs. Biochemical Society Transactions. 15(4). 728–730. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chris Benz Breakdown of academic impact, for papers by K Csóka Breakdown of academic impact, for papers by Ronald Drengler Breakdown of academic impact, for papers by Sheeba Irshad Breakdown of academic impact, for papers by Lidija Beketić-Orešković Breakdown of academic impact, for papers by Ornella Sanfilippo Breakdown of academic impact, for papers by G. R. Boniface Breakdown of academic impact, for papers by Kristin Padavic Breakdown of academic impact, for papers by Grażyna Pasz‐Walczak Breakdown of academic impact, for papers by Hiroko Taga
Rankless by CCL
2026